Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Contract win

1 May 2014 07:00

RNS Number : 0079G
Instem plc
01 May 2014
 



 

 

Instem plc

("Instem" or the "Company")

 

Contract Win

 

Instem's Provantis and Centrus solutions selected by WIL Research to replace and enhance its toxicology systems and processes worldwide

 

Instem (AIM: INS.L), a leading provider of IT solutions to the global early development healthcare market, announces today that it has been selected by WIL Research ("WIL") as its exclusive non-clinical technology partner, to optimise study-related processes at all WIL worldwide sites.

 

Key Facts

· Instem technology to replace all existing study management systems at WIL Research

· WIL Research selects all Provantis Preclinical Study Management modules

· Using Instem's Centrus-submit solution, WIL Research will become SEND (Standard for Exchange of Nonclinical Data) enabled

· WIL Research to leverage Instem's market leading SaaS model for worldwide deployment

 

WIL Research has approximately 1,200 staff offering a blend of technical and regulatory expertise in discovery support, product safety toxicological research, metabolism, bioanalytical chemistry, analytical chemistry and formulation services.

 

WIL Research has chosen Instem's entire Provantis software suite, including its Logbook ELN solution for paper form replacement, as part of a multi-year project. Instem's Toxicology Resource Planning ("TRP") solution is also a key element of the Provantis deployment, increasing efficiencies by enabling WIL Research to plan and manage studies and programs, allocate resources, benchmark against past studies and plan workloads for the future.

WIL Research has additionally selected Instem's Centrus-submit™ solution to support SEND, the standardised reporting format for nonclinical data. The submit solution suite converts data from any source system into SEND files and allows sponsors, CROs and regulators such as the FDA to share, visualise and analyse study data more efficiently.

 

David Spaight, Chief Executive Officer at WIL Research, commented: "We are delighted to announce our enhanced partnership with Instem on a global level to deploy a comprehensive solution for toxicology data collection and management across our facilities situated in the United States, the Netherlands and in France. By leveraging our existing experience with Provantis in France, this expanded platform will support growing demand from our clients requiring a common and seamless multi-site global study management solution."

 

Phil Reason, CEO of Instem plc, commented: "WIL's selection of Instem's technology to replace all of its existing study management systems is a significant endorsement of the quality of our solutions. WIL has been a valued customer of Instem for 7 years and we are excited that it has chosen to extend that relationship as part of the technology-driven transformation that it is embarking upon. Instem has already secured SaaS revenues in excess of $2 million per annum and this provides further evidence of the attractiveness of this solution to clients. Demand for our offering remains strong and the growing proportion of SaaS contracts is leading to increasing visibility going forward."

 

 

 

 

 

 

For further information, please contact:

 

Instem plc

www.instem.com

Phil Reason, CEO

Tel: +44 (0) 1785 825 600

Nigel Goldsmith, CFO

 

 

 

N+1 Singer (Nominated Adviser & Broker)

Tel: +44 (0) 20 7496 3000

Richard Lindley

 

Nick Owen

 

 

 

Walbrook PR Ltd

Tel: +44 (0) 20 7933 8780 or instem@walbrookpr.com

Bob Huxford

Mob: +44 (0)7747 635 908

Helen Cresswell

Mob: +44 (0)7841 917 679

 

 

 

About WIL Research

WIL Research is an interdisciplinary non-clinical contract research organisation providing product safety and toxicological assessment research and services to the international pharmaceutical, biotechnology, chemical, agricultural, veterinary, food and consumer products industries.

 

Find out more about WIL Research at www.wilresearch.com

 

 

About Instem

Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutionsfor data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.

 

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledgethrough the extraction and harmonisation of actionable scientific information.

 

Instem supports over 400 clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan.

 

To learn more about Instem solutions and its mission, please visit www.instem.com.

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAQKKDBCBKDPQN
Date   Source Headline
15th Feb 201811:05 amRNSSecond Price Monitoring Extn
15th Feb 201811:00 amRNSPrice Monitoring Extension
29th Jan 20187:00 amRNSDirector/PDMR Shareholding
23rd Jan 20185:27 pmRNSHolding(s) in Company
16th Jan 20187:01 amRNSContract Win
16th Jan 20187:00 amRNSTrading Statement
5th Oct 201711:30 amRNSHolding(s) in Company
29th Sep 201712:17 pmRNSIssue of Equity & Total Voting Rights
26th Sep 20177:00 amRNSHalf-year Report
21st Sep 20175:57 pmRNSHolding(s) in Company
4th Sep 20177:00 amRNSNotice of Results
31st May 20178:39 amRNSPayment of consideration and total voting rights
19th May 20175:00 pmRNSHolding(s) in Company
18th May 201710:24 amRNSResult of AGM
9th May 20172:25 pmRNSIssue of Equity and Total Voting Rights
28th Apr 20175:12 pmRNSHolding(s) in Company
26th Apr 20177:00 amRNSUS Government Contract
21st Apr 20177:00 amRNSPosting of Annual Report and Notice of AGM
4th Apr 201710:10 amRNSHolding(s) in Company
4th Apr 201710:10 amRNSHolding(s) in Company
29th Mar 20173:46 pmRNSHolding(s) in Company
28th Mar 20177:00 amRNSFinal Results
9th Mar 20177:00 amRNSInvestor Teach-in
7th Mar 20177:00 amRNSNotice of Results
16th Jan 20177:00 amRNSTrading Statement
9th Jan 20172:30 pmRNSAppointment of Chief Operating Officer
9th Jan 20177:00 amRNSGrowth & Innovation Forum
20th Dec 20165:23 pmRNSHolding(s) in Company
19th Dec 20164:58 pmRNSHolding(s) in Company
15th Dec 20167:00 amRNSRevised Earn Out Settlement
21st Nov 20167:00 amRNSTrading Statement
22nd Sep 20167:00 amRNSHolding(s) in Company
21st Sep 20168:08 amRNSIssue of Equity
19th Sep 20167:00 amRNSHalf-year Report
5th Sep 20163:40 pmRNSEarnings Enhancing Acquisition of Notocord®
24th Aug 20167:00 amRNSTrading Update and Notice of Half-Year Results
9th Jun 20165:32 pmRNSIssue of Equity
1st Jun 20161:55 pmRNSHolding(s) in Company
31st May 20167:00 amRNSAcquisition, Issue of Equity & Total Voting Rights
26th May 20165:42 pmRNSResult of AGM
19th May 20162:31 pmRNSHolding(s) in Company
16th May 20164:30 pmRNSIssue of Equity and Total Voting Rights
7th Apr 20169:42 amRNSHolding(s) in Company
5th Apr 20167:00 amRNSFinal Results
4th Apr 20167:00 amRNSFour SEND related contract wins
15th Mar 20167:00 amRNSTwo SEND Submit Contract Wins
14th Mar 20167:00 amRNSNotice of Results
3rd Mar 201610:56 amRNSHolding(s) in Company
29th Feb 20169:56 amRNSHolding(s) in Company (Correction)
26th Feb 20169:26 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.